Biotech New Highs: BioSpecifics Technologies (NASDAQ:BSTC), Five Prime Therapeutics (NASDAQ:FPRX), IGI Laboratories (NYSEMKT:IG), Durata Therapeutics (NASDAQ:DRTX)

BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 2.14% in last session and finished the day at $27.16. Traded volume was 61,391.00 shares in the last session and the average volume of the stock remained 27,510.00 shares. The beta of the stock remained 0.90. BioSpecifics Technologies Corp. … Continue reading Biotech New Highs: BioSpecifics Technologies (NASDAQ:BSTC), Five Prime Therapeutics (NASDAQ:FPRX), IGI Laboratories (NYSEMKT:IG), Durata Therapeutics (NASDAQ:DRTX)

Biotech Losers: Egalet Corp (NASDAQ:EGLT), Marina Biotech (OTCMKTS:MRNA), Conatus Pharmaceuticals (NASDAQ:CNAT), Acceleron Pharma (NASDAQ:XLRN)

Egalet Corporation (NASDAQ:EGLT) announced that its fourth quarter and year ended December 31, 2013 financial results will be released on Wednesday, March 26, 2014. Egalet Corp (NASDAQ:EGLT) stock performance was -5.53% in last session and finished the day at $17.41. Traded volume was 82,789.00 shares in the last session and the average volume of the stock remained 196,859.00 shares. The beta of the stock remained … Continue reading Biotech Losers: Egalet Corp (NASDAQ:EGLT), Marina Biotech (OTCMKTS:MRNA), Conatus Pharmaceuticals (NASDAQ:CNAT), Acceleron Pharma (NASDAQ:XLRN)

Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was 39.33% in last session and finished the day at … Continue reading Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

Biotech Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron Corporation (NASDAQ:GERN)

The iShares Biotechnology Indexhas fallen 2.46% in the last month of trading, and biotech stalwarts Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD ) are both down over 8%. What’s most surprising is that Celgene and Gilead are expected to have strong years in terms of earnings and the development of their respective clinical pipelines. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 0.53% in last session and … Continue reading Biotech Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron Corporation (NASDAQ:GERN)

Biotech Volatile Stocks: Geron Corporation (NASDAQ:GERN), Novavax (NASDAQ:NVAX), Aegerion Pharmaceuticals (NASDAQ:AEGR), CytRx Corporation (NASDAQ:CYTR)

Geron Corp. (NASDAQ:GERN) stock had its “positive” rating reiterated by equities research analysts at Wells Fargo & Co. in a research note issued to investors on Thursday, American Banking News.com reports.Geron Corporation (NASDAQ:GERN) stock performance was -2.73% in last session and finished the day at $1.78. Traded volume was 7,214,860 million shares in the last session and the average volume of the stock remained 5.57 … Continue reading Biotech Volatile Stocks: Geron Corporation (NASDAQ:GERN), Novavax (NASDAQ:NVAX), Aegerion Pharmaceuticals (NASDAQ:AEGR), CytRx Corporation (NASDAQ:CYTR)

Biotech New Highs: Five Prime Therapeutics Inc (NASDAQ:FPRX), Albany Molecular Research (NASDAQ:AMRI), Vanda Pharmaceuticals (NASDAQ:VNDA), Chimerix Inc (NASDAQ:CMRX)

Five Prime therapeutics Inc. (NASDAQ:FPRX) has announced it has entered into a collaboration agreement with Bristol Myers Squibb Co (NYSE:BMY) for the discovery and development of immune-oncology therapies. Five Prime Therapeutics Inc (NASDAQ:FPRX) stock performance was 22.61% in last session and finished the day at $22.99. Traded volume was 1,287,393 million shares in the last session and the average volume of the stock remained 120.37 … Continue reading Biotech New Highs: Five Prime Therapeutics Inc (NASDAQ:FPRX), Albany Molecular Research (NASDAQ:AMRI), Vanda Pharmaceuticals (NASDAQ:VNDA), Chimerix Inc (NASDAQ:CMRX)